592 related articles for article (PubMed ID: 28288821)
21. Combination of 7-hydroxycoumarin in a platinum(IV) complex derived from cisplatin enhanced cytotoxicity with multiple mechanisms of action.
Hua W; Zhao J; Hu W; Gou S
J Inorg Biochem; 2018 Sep; 186():17-23. PubMed ID: 29807243
[TBL] [Abstract][Full Text] [Related]
22. LYG-202 augments tumor necrosis factor-α-induced apoptosis via attenuating casein kinase 2-dependent nuclear factor-κB pathway in HepG2 cells.
Chen FH; Lu N; Zhang HW; Zhao L; He LC; Sun HP; You QD; Li ZY; Guo QL
Mol Pharmacol; 2012 Nov; 82(5):958-71. PubMed ID: 22909797
[TBL] [Abstract][Full Text] [Related]
23. Engineering liposomal nanoparticles of cholesterol-tethered amphiphilic Pt(iv) prodrugs with prolonged circulation time in blood.
Datta P; Bang S; Yue Z; Beach T; Stilgenbauer M; Wang H; Bowers DJ; Kurokawa M; Xiao H; Zheng YR
Dalton Trans; 2020 Jun; 49(24):8107-8113. PubMed ID: 32490446
[TBL] [Abstract][Full Text] [Related]
24. CK2 modulation of NF-kappaB, TP53, and the malignant phenotype in head and neck cancer by anti-CK2 oligonucleotides in vitro or in vivo via sub-50-nm nanocapsules.
Brown MS; Diallo OT; Hu M; Ehsanian R; Yang X; Arun P; Lu H; Korman V; Unger G; Ahmed K; Van Waes C; Chen Z
Clin Cancer Res; 2010 Apr; 16(8):2295-307. PubMed ID: 20371694
[TBL] [Abstract][Full Text] [Related]
25. Efficient co-delivery of a Pt(IV) prodrug and a p53 activator to enhance the anticancer activity of cisplatin.
Ma R; Wang Y; Yan L; Ma L; Wang Z; Chan HC; Chiu SK; Chen X; Zhu G
Chem Commun (Camb); 2015 May; 51(37):7859-62. PubMed ID: 25854514
[TBL] [Abstract][Full Text] [Related]
26. A novel pyrazole-containing indolizine derivative suppresses NF-κB activation and protects against TNBS-induced colitis via a PPAR-γ-dependent pathway.
Fu Y; Ma J; Shi X; Song XY; Yang Y; Xiao S; Li J; Gu WJ; Huang Z; Zhang J; Chen J
Biochem Pharmacol; 2017 Jul; 135():126-138. PubMed ID: 28336257
[TBL] [Abstract][Full Text] [Related]
27. Dual-targeting tumor cells hybrids derived from Pt(IV) species and NF-κB inhibitors enables cancer therapy through mitochondrial dysfunction and ER stress and overcomes cisplatin resistance.
Wang M; Li G; Jiang G; Cai J; Zhong W; Huang R; Liu Z; Huang X; Wang H
Eur J Med Chem; 2024 Feb; 266():116095. PubMed ID: 38215589
[TBL] [Abstract][Full Text] [Related]
28. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
29. Biotin-Pt (IV)-indomethacin hybrid: A targeting anticancer prodrug providing enhanced cancer cellular uptake and reversing cisplatin resistance.
Hu W; Fang L; Hua W; Gou S
J Inorg Biochem; 2017 Oct; 175():47-57. PubMed ID: 28700961
[TBL] [Abstract][Full Text] [Related]
30. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
31. A Pt(IV) Prodrug Combining Chlorambucil and Cisplatin: a Dual-Acting Weapon for Targeting DNA in Cancer Cells.
Montagner D; Tolan D; Andriollo E; Gandin V; Marzano C
Int J Mol Sci; 2018 Nov; 19(12):. PubMed ID: 30486477
[TBL] [Abstract][Full Text] [Related]
32. CXCL12/CXCR4 axis confers adriamycin resistance to human chronic myelogenous leukemia and oroxylin A improves the sensitivity of K562/ADM cells.
Wang Y; Miao H; Li W; Yao J; Sun Y; Li Z; Zhao L; Guo Q
Biochem Pharmacol; 2014 Aug; 90(3):212-25. PubMed ID: 24858801
[TBL] [Abstract][Full Text] [Related]
33. LW-214, a newly synthesized flavonoid, induces intrinsic apoptosis pathway by down-regulating Trx-1 in MCF-7 human breast cells.
Pan D; Li W; Miao H; Yao J; Li Z; Wei L; Zhao L; Guo Q
Biochem Pharmacol; 2014 Feb; 87(4):598-610. PubMed ID: 24374359
[TBL] [Abstract][Full Text] [Related]
34. Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy.
Mowday AM; Ashoorzadeh A; Williams EM; Copp JN; Silva S; Bull MR; Abbattista MR; Anderson RF; Flanagan JU; Guise CP; Ackerley DF; Smaill JB; Patterson AV
Biochem Pharmacol; 2016 Sep; 116():176-87. PubMed ID: 27453434
[TBL] [Abstract][Full Text] [Related]
35. A cisplatin-based platinum(IV) prodrug containing a glutathione s-transferase inhibitor to reverse cisplatin-resistance in non-small cell lung cancer.
Chen H; Wang X; Gou S
J Inorg Biochem; 2019 Apr; 193():133-142. PubMed ID: 30731264
[TBL] [Abstract][Full Text] [Related]
36. Breakdown of chemo-immune resistance by a TDO2-targeted Pt(IV) prodrug via attenuating endogenous Kyn-AhR-AQP4 metabolic circuity and TLS-promoted genomic instability.
Chen F; Xu G; Tian W; Gou S
Biochem Pharmacol; 2021 Nov; 193():114785. PubMed ID: 34562469
[TBL] [Abstract][Full Text] [Related]
37. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
38. Monochalcoplatin: An Actively Transported, Quickly Reducible, and Highly Potent Pt
Ma L; Wang N; Ma R; Li C; Xu Z; Tse MK; Zhu G
Angew Chem Int Ed Engl; 2018 Jul; 57(29):9098-9102. PubMed ID: 29806087
[TBL] [Abstract][Full Text] [Related]
39. Platinum(IV) Complexes of
Papadia P; Micoli K; Barbanente A; Ditaranto N; Hoeschele JD; Natile G; Marzano C; Gandin V; Margiotta N
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230896
[TBL] [Abstract][Full Text] [Related]
40. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
Jin S; Guo Y; Song D; Zhu Z; Zhang Z; Sun Y; Yang T; Guo Z; Wang X
Inorg Chem; 2019 May; 58(9):6507-6516. PubMed ID: 31013065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
